Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$70.27 USD

70.27
5,424,803

+1.80 (2.63%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $70.26 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will UnitedHealth's (UNH) UnitedHealthcare Unit Aid Q1 Earnings?

by Zacks Equity Research

UnitedHealth's (UNH) first-quarter results are expected to benefit from an increase in UnitedHealthcare's Community & State revenues and the number of people it served.

Elevance Health (ELV) Brand Inks Deal to Better Serve Georgia

by Zacks Equity Research

Elevance Health's (ELV) brand, Anthem Blue Cross and Blue Shield, collaborates to make the benefits of Piedmont's healthcare network available to its members across specific Georgia regions.

Tenet Healthcare (THC) Soars 76% in a Year: What Lies Ahead?

by Zacks Equity Research

Tenet Healthcare (THC) remains well-poised for growth on increased admissions and surgeries in the Hospital segment, acquisitions, debt repayment efforts and solid operating cash flows.

Here's Why Investors Should Hold Teladoc (TDOC) Stock Now

by Zacks Equity Research

Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.

If You Invested $1000 in Edwards Lifesciences a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Delcath Systems (DCTH) delivered earnings and revenue surprises of 28.36% and 12.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging Edwards Lifesciences (EW) This Year?

by Zacks Equity Research

Here is how Edwards Lifesciences (EW) and Avinger (AVGR) have performed compared to their sector so far this year.

Compelling Reasons to Hold on to UnitedHealth Group (UNH) Stock

by Zacks Equity Research

UnitedHealth Group (UNH) remains well-poised for growth on the back of improved premiums, acquisitions and partnerships, an in-demand telehealth services suite and solid cash-generating abilities.

Edwards Lifesciences (EW) Up 21.8% YTD: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.

IQVIA (IQV) Up 5.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Edwards Lifesciences (EW) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Edwards Lifesciences (EW) outperforms the industry, owing to a robust 2023 fourth-quarter performance, as well as the strong potential in the TMTT division.

Nalak Das headshot

Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024

by Nalak Das

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.

Zacks Investment Ideas feature highlights: Tenet Healthcare and HCA Healthcare

by Zacks Equity Research

Tenet Healthcare and HCA Healthcare are part of the Zacks Investment Ideas article.

Bryan Hayes headshot

Medical Devices ETF Hits 52-Week High: Stocks to Watch

by Bryan Hayes

Historically viewed as a defensive area, health care also boasts many growth aspects and benefits from advances in technology.

Edwards Lifesciences' (EW) SAPIEN TAVR Study Outcome Favorable

by Zacks Equity Research

Edwards Lifesciences' (EW) recent study provides insights into the actual performance of small Edwards valves and reaffirms the excellent outcomes for patients receiving SAPIEN TAVR.

Here's How Much a $1000 Investment in Edwards Lifesciences Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Edwards Lifesciences (EW) Up 2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Edwards (EW) Gains From RESILIA's Global Adoption, TAVR Growth

by Zacks Equity Research

With the Critical Care spin-off, Edwards (EW) is looking to pursue growth in TAVR, TMTT and Surgical, as well as new investments in interventional heart failure technologies.

HOLX or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Here's Why You Should Buy Edward Lifesciences (EW) Stock Now

by Zacks Equity Research

Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.

If You Invested $1000 in Edwards Lifesciences a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Fresenius Medical (FMS) Q4 Earnings Beat, Operating Margin Up

by Zacks Equity Research

Fresenius Medical's (FMS) fourth-quarter revenues suffer due to unfavorable currency movement. However, the company???s transformational plans continue to benefit its operating income.

Reasons to Add Veeva Systems (VEEV) to Your Portfolio Now

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

Here's Why You Should Add Masimo (MASI) to Your Portfolio Now

by Zacks Equity Research

Masimo's (MASI) R&D activities raise optimism about the stock.